Olezarsen & Fibrates: Lower Triglycerides Effectively

Olezarsen: Novel ApoC-III Inhibitor Offers New Hope for Triglyceride Management

A new therapeutic approach to lowering triglycerides is on the horizon with olezarsen, an apolipoprotein C-III (apoC-III) inhibitor. Clinicians and pharmacists should understand its unique mechanism of action and potential safety considerations, which differ from existing triglyceride-lowering therapies.

Olezarsen represents a shift in how high triglycerides are addressed,targeting a key protein involved in fat metabolism. According to a leading expert, apolipoprotein C3 functions as an inhibitor of lipoprotein lipase, a crucial enzyme for clearing triglycerides, and also hinders the liver’s ability to absorb triglyceride-rich lipoproteins. By reducing the amount of ApoC-3 protein, olezarsen effectively activates lipoprotein lipase and enhances the liver’s uptake of these fats, leading to a ample reduction in triglyceride levels.

Did you know?-apoc-III inhibition is a novel approach to triglyceride reduction, differing from conventional therapies like fibrates and omega-3 fatty acids which primarily affect lipoprotein lipase activity.

Understanding the Lipid Profile shift

While olezarsen dramatically lowers triglycerides, it also presents a unique effect on other lipid markers. As triglyceride-rich particles are broken down into smaller, denser particles, there is a corresponding increase in LDL cholesterol levels. However, this increase does not necessarily translate to increased cardiovascular risk. One analyst noted that the overall atherogenic lipoprotein count,as measured by non-HDL cholesterol and apolipoprotein B,is significantly reduced,indicating a favorable overall lipid profile.

“Even though LDL goes up slightly,the overall atherogenic risk and lipid profile is favorable and decreases,” the expert explained.

Pro tip:-Monitor liver function tests (LFTs) during olezarsen treatment, notably with the 80 mg dose, as moderate elevations were observed in clinical trials.

Safety and Monitoring Parameters

Clinical trials evaluating olezarsen have identified specific safety considerations. A moderate elevation in liver function tests (LFTs) was observed with the 80 mg dose, reaching approximately five times the upper limit of normal. Importantly, no cases meeting Hy’s law criteria were reported. The 50 mg dose did not demonstrate this association with elevated transaminases.

Moreover, a slight increase in hemoglobin A1C-around 0.25 percentage points-was noted in patients with pre-existing diabetes. This effect appeared to level off after treatment initiation and is similar to the small A1C rise sometimes seen with statins. Despite these laboratory abnormalities, the benefits of olezarsen-including a 65% reduction in triglycerides and a decreased risk of acute pancreatitis-are considered to outweigh the risks.

Reader question:-Can olezarsen be used in patients already on statins? Yes, studies show olezarsen is effective even when combined with standard-of-care therapies like statins, fibrates, and omega-3 fatty acids.

Positioning Olezarsen in Current Treatment Paradigms

Olezarsen is not intended to replace existing triglyceride-lowering treatments but rather to complement them. Studies indicate that the drug works effectively in patients already receiving standard-of-care therapies, including statins, fibrates, and omega-3 fatty acids. In fact, olezarsen demonstrated a particularly synergistic effect when combined with fibrates.

“Fibrates also work through lipoprotein lipase, so it truly seems like the two drugs in combination have a synergistic effect,” a senior official stated. “It may be that we use these two together more frequently, as combination therapy-just like we do in other conditions.”

This suggests that a combination of fibrates and ApoC-3 inhibitors could become a more common approach to managing severe hypertriglyceridemi